Aprogen, Inc Logo

Aprogen, Inc

Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.

007460 | KO

Overview

Corporate Details

ISIN(s):
KR7007460009
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 545 경기도 성남시 중원구 둔촌대로545, 비1층 (상대원동, 한라시그마밸리), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprogen, Inc. is a biopharmaceutical company specializing in the development and manufacturing of biologics. Leveraging proprietary technologies in antibody and recombinant protein engineering, the company creates both novel drugs and biosimilars. Its product pipeline focuses on addressing various medical needs, including treatments for degenerative arthritis and triple-negative breast cancer. Aprogen develops its own portfolio of biologics alongside biosimilar products, aiming to make advanced medicines more accessible in the global pharmaceutical market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 151.1 KB
2025-09-17 00:00
Regulatory News Service
투자판단관련주요경영사항
Korean 15.5 KB
2025-09-03 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)(자회사의 주요경영사항) (제3자배정)
Korean 31.1 KB
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 157.0 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 149.8 KB
2025-08-19 00:00
Regulatory News Service
투자판단관련주요경영사항 (독점실시권 라이선스 계약(면역항암제 기술도입 계약))
Korean 10.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 7.7 MB
2025-07-31 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Korean 10.4 KB
2025-07-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 155.6 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 148.5 KB
2025-06-27 00:00
Capital/Financing Update
[기재정정]주권관련사채권의처분결정(종속회사의주요경영사항)
Korean 23.5 KB
2025-06-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.3 KB
2025-06-09 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-06-02 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-05-30 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 146.4 KB

Automate Your Workflow. Get a real-time feed of all Aprogen, Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprogen, Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprogen, Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS

Talk to a Data Expert

Have a question? We'll get back to you promptly.